LifeWealth Investments LLC Purchases New Shares in Thermo Fisher Scientific Inc. $TMO

LifeWealth Investments LLC purchased a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 565 shares of the medical research company’s stock, valued at approximately $229,000.

Several other institutional investors have also added to or reduced their stakes in TMO. CBIZ Investment Advisory Services LLC boosted its stake in Thermo Fisher Scientific by 137.5% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 33 shares during the period. Anderson Financial Strategies LLC bought a new stake in shares of Thermo Fisher Scientific during the 1st quarter valued at $30,000. Keystone Global Partners LLC bought a new stake in shares of Thermo Fisher Scientific during the 1st quarter valued at $31,000. DiNuzzo Private Wealth Inc. lifted its position in shares of Thermo Fisher Scientific by 406.7% during the 2nd quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 61 shares during the period. Finally, HighMark Wealth Management LLC lifted its position in shares of Thermo Fisher Scientific by 140.6% during the 2nd quarter. HighMark Wealth Management LLC now owns 77 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 45 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on TMO. Leerink Partners upped their target price on Thermo Fisher Scientific from $545.00 to $580.00 and gave the company an “outperform” rating in a research report on Wednesday. UBS Group upped their target price on Thermo Fisher Scientific from $500.00 to $590.00 and gave the company a “neutral” rating in a research report on Thursday. Royal Bank Of Canada set a $561.00 target price on Thermo Fisher Scientific and gave the company an “outperform” rating in a research report on Tuesday, September 2nd. William Blair started coverage on Thermo Fisher Scientific in a research report on Monday, August 18th. They set an “outperform” rating for the company. Finally, Hsbc Global Res downgraded Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 24th. Nineteen investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $595.75.

Thermo Fisher Scientific Price Performance

Shares of TMO stock opened at $571.94 on Friday. The company has a quick ratio of 1.50, a current ratio of 1.50 and a debt-to-equity ratio of 0.62. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $610.97. The company has a market cap of $215.97 billion, a P/E ratio of 33.04, a P/E/G ratio of 3.25 and a beta of 0.77. The business has a fifty day simple moving average of $502.38 and a 200 day simple moving average of $452.23.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, topping the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The business had revenue of $11.12 billion during the quarter, compared to the consensus estimate of $10.90 billion. During the same period in the prior year, the company earned $5.28 EPS. Thermo Fisher Scientific’s revenue for the quarter was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $500.96, for a total value of $5,009,600.00. Following the completion of the transaction, the chief executive officer owned 115,174 shares of the company’s stock, valued at $57,697,567.04. This represents a 7.99% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Joseph R. Holmes sold 385 shares of the company’s stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the transaction, the chief accounting officer directly owned 2,319 shares of the company’s stock, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 29,666 shares of company stock valued at $13,990,971. Insiders own 0.33% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.